Free Trial
NASDAQ:STTK

Shattuck Labs Q2 2023 Earnings Report

Shattuck Labs logo
$0.75 +0.02 (+2.32%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Shattuck Labs EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Shattuck Labs Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.36 million
Beat/Miss
Missed by -$160.00 thousand
YoY Revenue Growth
N/A

Shattuck Labs Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Shattuck Labs' Q2 2025 earnings is scheduled for Thursday, August 7, 2025

Shattuck Labs Earnings Headlines

A grave, grave error.
Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one analyst who predicted the collapse of Fannie Mae and GM says the AI giant is now headed for a brutal crash… and it could hit as soon as this year.
Shattuck Labs, Inc. (STTK) - Yahoo Finance
See More Shattuck Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email.

About Shattuck Labs

Shattuck Labs (NASDAQ:STTK), a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

View Shattuck Labs Profile

More Earnings Resources from MarketBeat